Is IQVIA Holdings Stock Outperforming the S&P 500?

Core Insights - IQVIA Holdings Inc. is a significant player in the life sciences industry, providing clinical research services and healthcare intelligence, with a market cap of $38.4 billion [1][2] Company Overview - The company operates through three main segments: Technology & Analytics (TAS), Research & Development (R&DS), and Contract Sales & Medical Solutions (CSMS) [1] - IQVIA is categorized as a large-cap stock, reflecting its substantial size and influence in the diagnostics and research industry [2] Stock Performance - IQVIA's stock reached a 52-week high of $234.29 on November 25 and is currently trading 3% below that peak [3] - Over the past three months, IQVIA's stock prices have increased by 23.1%, outperforming the S&P 500 Index, which gained 6.2% during the same period [3] - Year-to-date, IQVIA's stock has gained 15.6%, while over the past 52 weeks, it has increased by 13%, compared to the S&P 500's gains of 16.5% and 13.2%, respectively [4] Financial Performance - Following the release of better-than-expected Q3 results on October 28, IQVIA's stock saw a slight uptick [5] - The company reported a 5.2% year-over-year growth in topline revenue, reaching $4.1 billion, which exceeded market expectations [5] - Adjusted EPS grew by 5.6% year-over-year to $3.00, surpassing consensus estimates by 1.4% [5] Competitive Position - IQVIA has outperformed its peer Agilent Technologies, Inc., which recorded 11.1% gains year-to-date and 7.2% returns over the past year [6]